European journal of cancer (Oxford, England : 1990) · 2026
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erard Théo, Quéreux Gaelle, Amini-Adle Mona, Montaudié Henri, Charles Julie, Puyraveau Marc, Jeudy Géraldine, Bernard Philippe, Grange Florent, Legoupil Delphine, Zehou Ouidad, Celerier Philippe, Lesage Candice, Khammari Amir, Aubin François, Nardin Charlée
Аннотация
BACKGROUND: The approval of adjuvant treatment with anti-PD-1 antibodies (anti-PD-1) and BRAF and MEK inhibitors (BRAFi/MEKi) for resected stage III/IV melanoma was based on randomized controlled trials demonstrating a benefit in recurrence-free survival (RFS). However, none showed a significant impact on overall survival (OS). We aimed to evaluate the OS impact of adjuvant therapies in real-world settings.
METHODS: TAMARIS is a national multicenter retrospective study evaluating the efficacy of anti-PD-1 and BRAFi/MEKi for resected stage III melanoma in a French real-life prospective database (RIC-Mel). Patients with resectable stage III melanoma (AJCC 8th edition), who underwent complete surgical resection between 2018 and 2023 were included. OS in patients who received an adjuvant treatment (adjuvant group) was compared to those who did not receive systemic therapies (control group). Associations between the adjuvant strategy (adjuvant treatment versus observation) and OS were evaluated using a Cox regression model and inverse probability treatment weighting (IPTW) in order to limit potential biases. Subgroup analyses by baseline characteristics and treatment regimens were also conducted.
RESULTS: Among the 1016 patients (median age: 60 years) included, 701 (69%) received adjuvant therapies with either anti-PD-1 (n = 588) or BRAFi/MEKi (n = 113). The median treatment duration was 10.9 months, and the median follow-up was 29.6 months. OS was significantly higher in the adjuvant group compared to the control group (HR: 0.62, [IC95%, 0.47-0.80], P = 0.003) confirmed in multivariate analysis and after IPTW-adjustment (HR: 0.68, [IC95%, 0.49-0.94], P = 0.020). In subgroup analyses, adjuvant treatment had a significant positive impact on OS across most subgroups, but not for stage IIIA.
CONCLUSION: These real-world data indicate a significant OS benefit of adjuvant therapy in patients with AJCC8 stage III melanoma, but not in those with stage IIIA disease.
METHODS: TAMARIS is a national multicenter retrospective study evaluating the efficacy of anti-PD-1 and BRAFi/MEKi for resected stage III melanoma in a French real-life prospective database (RIC-Mel). Patients with resectable stage III melanoma (AJCC 8th edition), who underwent complete surgical resection between 2018 and 2023 were included. OS in patients who received an adjuvant treatment (adjuvant group) was compared to those who did not receive systemic therapies (control group). Associations between the adjuvant strategy (adjuvant treatment versus observation) and OS were evaluated using a Cox regression model and inverse probability treatment weighting (IPTW) in order to limit potential biases. Subgroup analyses by baseline characteristics and treatment regimens were also conducted.
RESULTS: Among the 1016 patients (median age: 60 years) included, 701 (69%) received adjuvant therapies with either anti-PD-1 (n = 588) or BRAFi/MEKi (n = 113). The median treatment duration was 10.9 months, and the median follow-up was 29.6 months. OS was significantly higher in the adjuvant group compared to the control group (HR: 0.62, [IC95%, 0.47-0.80], P = 0.003) confirmed in multivariate analysis and after IPTW-adjustment (HR: 0.68, [IC95%, 0.49-0.94], P = 0.020). In subgroup analyses, adjuvant treatment had a significant positive impact on OS across most subgroups, but not for stage IIIA.
CONCLUSION: These real-world data indicate a significant OS benefit of adjuvant therapy in patients with AJCC8 stage III melanoma, but not in those with stage IIIA disease.